1.Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA. Cancer J. Clin. 68, 7–30 (2018).
2.Jain, K. K. The Handbook of Nanomedicine. (Humana Press, 2008).
3.Hu, D. & Shilatifard, A. Epigenetics of hematopoiesis and hematological malignancies. Genes Dev. 30, 2021–2041 (2016).
4.Siegel, R. L., Miller, K. D. & Ahmedin Jemal, D. Cancer Statistics, 2016. CA CANCER J CLIN 66, 7–30 (2016).
5.Editor, C. M. E. & Tefferi, A. Continuing medical education activity in American Journal of Hematology. Am. J. Hematol. 87, 1037–1045 (2012).
6.Jerkeman, M. et al. Targeting of B-cell receptor signalling in B-cell malignancies. J. Intern. Med. 282, 415–428 (2017).
7.Hasan, S. A Review on Nanoparticles : Their Synthesis and Types. Res. J. Recent. Sci. 4, 9–11 (2015).
8.Nikalje, A. P. Nanotechnology and its applications in agriculture. Med chem 5, 081–089 (2015).
9.Venkatraman, S. Has nanomedicine lived up to its promise? Nanotechnology 25, (2014).
10.Cartaxo, A. Nanoparticles types and properties – understanding these promising devices in the biomedical area. Int. J. Nanomedicine 1–8 (2018).
11.Dawidczyk, C. M., Russell, L. M. & Searson, P. C. Nanomedicines for cancer therapy: State-of-the-art and limitations to pre-clinical studies that hinder future developments. Front. Chem. 2, 1–13 (2014).
12.Ventola, C. L. Progress in Nanomedicine: Approved and Investigational Nanodrugs. P T 42, 742–755 (2017).
13.Yang, H. et al. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Oncotarget 5, 8188–8201 (2014).
14.Vinhas, R., Mendes, R., Fernandes, A. R. & Baptista, P. V. Nanoparticles-Emerging potential for managing leukemia and lymphoma. Front. Bioeng. Biotechnol. 5, 1–10 (2017).
